See more : LOGOS HOLDINGS INC. (205A.T) Income Statement Analysis – Financial Results
Complete financial analysis of Innate Pharma S.A. (IPHA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Innate Pharma S.A., a leading company in the Biotechnology industry within the Healthcare sector.
- Mason Industrial Technology, Inc. (MITGW) Income Statement Analysis – Financial Results
- Green Dot Corporation (0J0N.L) Income Statement Analysis – Financial Results
- Canada Goose Holdings Inc. (GOOS) Income Statement Analysis – Financial Results
- Unipol Gruppo S.p.A. (UFGSY) Income Statement Analysis – Financial Results
- Sunac China Holdings Limited (1918.HK) Income Statement Analysis – Financial Results
Innate Pharma S.A. (IPHA)
About Innate Pharma S.A.
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 51.90M | 49.64M | 12.11M | 56.83M | 68.97M | 79.89M | 32.63M | 56.16M | 17.91M | 907.00K | 12.47M | 10.38M | 11.74M | 4.32M | 7.72M | 12.92M | 14.29M | 6.20M | 1.30M |
Cost of Revenue | 56.02M | 51.66M | 47.00M | 3.04M | 45.16M | 69.56M | 67.00M | 48.63M | 29.91M | 12.09M | 7.58M | 6.86M | 1.64M | 3.43M | 3.35M | 2.56M | 2.77M | 2.20M | 944.00K |
Gross Profit | -4.12M | -2.02M | -34.89M | 53.79M | 23.82M | 10.34M | -34.37M | 7.53M | -12.00M | -11.18M | 4.89M | 3.51M | 10.10M | 893.00K | 4.37M | 10.37M | 11.52M | 3.99M | 356.00K |
Gross Profit Ratio | -7.94% | -4.08% | -288.08% | 94.65% | 34.53% | 12.94% | -105.33% | 13.41% | -67.02% | -1,232.64% | 39.22% | 33.86% | 86.05% | 20.67% | 56.62% | 80.21% | 80.64% | 64.47% | 27.38% |
Research & Development | 56.02M | 51.66M | 47.00M | 58.61M | 1.60M | 69.56M | 67.00M | 48.63M | 29.91M | 22.67M | 15.13M | 13.42M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 11.75M | 14.47M | 15.99M | 31.25M | 40.73M | 18.14M | 15.66M | 8.88M | 5.59M | 12.50M | 10.38M | 9.33M | 0.00 | 6.27M | 8.52M | 0.00 | 0.00 | 1.64M | 938.00K |
Selling & Marketing | 0.00 | 7.96M | 9.53M | -861.00K | 8.85M | 1.11M | 527.00K | 450.00K | 288.00K | 314.00K | 283.00K | 406.00K | 9.79M | 7.06M | 10.06M | 0.00 | 0.00 | 207.00K | 139.00K |
SG&A | 11.75M | 22.44M | 25.52M | 30.39M | 49.58M | 19.25M | 16.18M | 9.33M | 5.88M | 12.82M | 10.67M | 9.73M | 9.79M | 7.06M | 10.06M | 0.00 | 0.00 | 1.84M | 1.08M |
Other Expenses | -3.20M | -8.04M | -12.59M | -13.62M | -309.00K | -14.06M | -10.57M | -9.37M | -7.11M | -19.00K | 179.00K | 2.00K | 7.88M | 32.00K | 909.00K | 21.37M | 20.62M | 9.34M | 5.69M |
Operating Expenses | 64.57M | 66.06M | 59.94M | 75.38M | 50.87M | 74.75M | 72.61M | 48.59M | 28.68M | 8.76M | 7.66M | 6.88M | 17.67M | 14.58M | 19.90M | 21.37M | 20.62M | 11.18M | 6.77M |
Cost & Expenses | 64.57M | 66.06M | 59.94M | 75.38M | 96.03M | 74.75M | 72.61M | 48.59M | 28.68M | 20.85M | 15.24M | 13.75M | 19.31M | 18.01M | 23.25M | 23.93M | 23.38M | 13.38M | 7.72M |
Interest Income | 3.18M | 4.78M | 6.34M | 4.86M | 1.62M | 1.58M | 1.25M | 0.00 | 27.00K | 445.00K | 244.00K | 34.00K | 945.00K | 541.00K | 0.00 | 1.19M | 212.00K | 1.20M | 280.00K |
Interest Expense | 640.00K | 5.32M | 4.00M | 6.76M | 204.00K | 102.00K | 113.00K | 124.00K | 139.00K | 0.00 | 0.00 | 225.00K | 520.00K | 509.00K | 0.00 | 36.00K | 39.00K | 2.00K | 0.00 |
Depreciation & Amortization | 5.09M | 4.42M | 4.57M | 9.39M | 16.53M | 7.40M | 4.40M | 3.26M | 2.66M | 2.34M | 880.00K | 839.00K | 901.00K | 1.10M | 1.02M | 539.00K | 536.00K | 298.00K | 301.00K |
EBITDA | -1.84M | -61.30M | -43.23M | 43.11M | -20.86M | -3.30M | -35.65M | 10.83M | -8.09M | -17.14M | -1.91M | -1.76M | -5.80M | -12.32M | -14.47M | -12.48M | -8.50M | -6.94M | -6.11M |
EBITDA Ratio | -3.54% | 68.00% | -304.53% | 75.85% | -12.88% | 15.48% | -109.25% | 20.73% | -45.18% | -1,967.81% | -17.70% | -27.62% | -47.19% | -291.44% | -187.48% | -80.99% | -59.51% | -91.90% | -448.31% |
Operating Income | -12.67M | -11.65M | -47.83M | -13.69M | -27.05M | 5.15M | -39.98M | 7.57M | -10.77M | -19.97M | -2.79M | -3.39M | -7.57M | -13.69M | -15.54M | -11.01M | -9.09M | -7.24M | -6.42M |
Operating Income Ratio | -24.41% | -23.47% | -394.86% | -24.09% | -39.22% | 6.44% | -122.53% | 13.48% | -60.16% | -2,201.32% | -22.40% | -32.63% | -64.48% | -316.90% | -201.33% | -85.16% | -63.62% | -116.85% | -493.46% |
Total Other Income/Expenses | 5.10M | -547.00K | 2.35M | -15.53M | 6.29M | -2.43M | -8.03M | 5.37M | 4.07M | 319.00K | -99.00K | 183.00K | 590.00K | 32.00K | 909.00K | 1.15M | 173.00K | 1.20M | 286.00K |
Income Before Tax | -7.57M | -57.97M | -45.48M | -63.98M | -20.76M | 2.72M | -48.02M | 12.94M | -6.71M | -19.65M | -2.89M | -3.20M | -6.98M | -13.66M | -14.63M | -9.85M | -8.92M | -6.04M | -6.13M |
Income Before Tax Ratio | -14.59% | -116.79% | -375.48% | -112.58% | -30.10% | 3.40% | -147.15% | 23.04% | -37.45% | -2,166.15% | -23.19% | -30.83% | -59.45% | -316.16% | -189.55% | -76.23% | -62.41% | -97.53% | -471.46% |
Income Tax Expense | 0.00 | 41.13M | 13.66M | 6.76M | 206.00K | -333.00K | 368.00K | 301.00K | 139.00K | -24.00K | -51.00K | -146.00K | 1.13M | 0.00 | 46.00K | 0.00 | 51.00K | 1.20M | 286.00K |
Net Income | -7.57M | -99.10M | -59.14M | -70.75M | -20.97M | 3.05M | -48.39M | 12.64M | -6.71M | -19.65M | -2.89M | -3.20M | -6.98M | -13.66M | -14.63M | -9.85M | -8.92M | -6.04M | -6.13M |
Net Income Ratio | -14.59% | -199.65% | -488.24% | -124.48% | -30.40% | 3.82% | -148.28% | 22.51% | -37.45% | -2,166.15% | -23.19% | -30.83% | -59.45% | -316.16% | -189.55% | -76.23% | -62.41% | -97.53% | -471.46% |
EPS | -0.09 | -1.24 | -0.74 | -0.90 | -0.31 | 0.05 | -0.89 | 0.23 | -0.13 | -0.39 | -0.07 | -0.08 | -0.19 | -0.36 | -0.56 | -0.38 | -0.36 | -0.34 | -0.41 |
EPS Diluted | -0.09 | -1.24 | -0.74 | -0.90 | -0.31 | 0.05 | -0.89 | 0.23 | -0.13 | -0.39 | -0.07 | -0.08 | -0.19 | -0.36 | -0.56 | -0.38 | -0.36 | -0.34 | -0.41 |
Weighted Avg Shares Out | 80.45M | 79.64M | 79.54M | 78.93M | 66.91M | 58.78M | 54.35M | 53.87M | 51.58M | 50.15M | 38.70M | 37.80M | 37.69M | 37.44M | 26.30M | 25.67M | 25.08M | 17.77M | 14.90M |
Weighted Avg Shares Out (Dil) | 80.45M | 79.64M | 79.54M | 78.93M | 66.91M | 58.78M | 54.35M | 53.87M | 53.40M | 50.15M | 38.70M | 37.80M | 37.69M | 37.44M | 26.30M | 25.67M | 25.08M | 17.77M | 14.90M |
All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
Innate Pharma Announces Its Participation in Upcoming Investor Conference
Innate Pharma Files Its 2023 Universal Registration Document (Document d'enregistrement Universel) and 2023 Annual Report on Form 20-F
Innate Pharma S.A. (IPHA) Q4 2023 Earnings Call Transcript
Innate Pharma Reports Full Year 2023 Financial Results and Business Update
Innate Pharma Announces Its Participation to Upcoming Investor Conference
Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results
Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin's Lymphoma
Source: https://incomestatements.info
Category: Stock Reports